BUND FINANCE › Stocks › ABBV
AbbVie Inc. (ABBV)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 3:59 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +3.18% above its 50-day average.
- It is +18.42% above its 200-day average (long-term uptrend).
- It sits at 85% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$56.2B | US$58.1B | US$54.3B | US$56.3B | US$61.2B |
| Net income | US$11.5B | US$11.8B | US$4.9B | US$4.3B | US$4.2B |
| EPS (diluted) | 6.45 | 6.63 | 2.72 | 2.39 | 2.37 |
| Gross margin | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| Operating margin | 31.9% | 31.2% | 23.5% | 16.2% | 24.7% |
| Net margin | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| Free cash flow | US$22.0B | US$24.2B | US$22.1B | US$17.8B | US$17.8B |
| Total debt | US$77.6B | US$64.2B | US$60.1B | US$67.8B | US$69.1B |
| Cash | US$9.7B | US$9.2B | US$12.8B | US$5.5B | US$5.2B |
Compound annual growth: revenue 2.1% · net income -22.2% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 49.1x | 54.5x | 27.1x |
| EV / EBITDA | 22.9x | 19.5x | 16.5x |
| Operating margin | 35.2% | — | 3.6% |
| Net margin | 15.7% | — | -0.0% |
| Debt / equity | — | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice